Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miklos Rohla

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
The American Journal of Cardiology|January 28, 2014
Influence of high-dose highly efficient statins on short-term mortality in patients undergoing percutaneous coronary intervention with stenting for acute coronary syndromesIoannis Tentzeris, Miklos Rohla, Rudolf Jarai, et al.
Thrombosis Research|August 24, 2020
Von Willebrand Factor and ADAMTS13 and long-term outcomes in patients undergoing percutaneous coronary interventionMaximilian Tscharre, Ioannis Tentzeris, Birgit Vogel, et al.
International Journal of Cardiology|February 21, 2015
Long-term mortality of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation for acute and stable coronary artery diseaseMiklos Rohla, Christoph Kleine Vennekate, Ioannis Tentzeris, et al.
International Journal of Cardiology|September 18, 2018
Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registriesGiuseppe Patti, Ladislav Pecen, Markus Lucerna, et al.
European Journal of Clinical Investigation|July 19, 2019
Impact of platelet turnover on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary interventionMaximilian Tscharre, Serdar Farhan, Veronika Bruno, et al.
Journal of Hypertension|November 12, 2015
Predictors of response to renal denervation for resistant arterial hypertension: a single center experienceMiklos Rohla, Alexander Nahler, Thomas Lambert, et al.
Wiener Klinische Wochenschrift|September 15, 2016
Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization : A real world experienceMiklos Rohla, Ioannis Tentzeris, Matthias K Freynhofer, et al.
Frontiers in Cardiovascular Medicine|March 29, 2022
Neurotensin and Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary InterventionMaximilian Tscharre, Serdar Farhan, Matthias K Freynhofer, et al.
The American Journal of Cardiology|July 24, 2017
Usefulness of Elevated Levels of Growth Differentiation Factor-15 to Classify Patients With Acute Coronary Syndrome Having Percutaneous Coronary Intervention Who Would Benefit from High-Dose Statin TherapyIoannis Tentzeris, Serdar Farhan, Matthias Karl Freynhofer, et al.
BMJ Open|April 1, 2019
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)Miklos Rohla, Thomas W Weiss, Ladislav Pecen, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
The American Journal of Cardiology|January 28, 2014
Influence of high-dose highly efficient statins on short-term mortality in patients undergoing percutaneous coronary intervention with stenting for acute coronary syndromesIoannis Tentzeris, Miklos Rohla, Rudolf Jarai, et al.
Thrombosis Research|August 24, 2020
Von Willebrand Factor and ADAMTS13 and long-term outcomes in patients undergoing percutaneous coronary interventionMaximilian Tscharre, Ioannis Tentzeris, Birgit Vogel, et al.
International Journal of Cardiology|February 21, 2015
Long-term mortality of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation for acute and stable coronary artery diseaseMiklos Rohla, Christoph Kleine Vennekate, Ioannis Tentzeris, et al.
International Journal of Cardiology|September 18, 2018
Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registriesGiuseppe Patti, Ladislav Pecen, Markus Lucerna, et al.
European Journal of Clinical Investigation|July 19, 2019
Impact of platelet turnover on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary interventionMaximilian Tscharre, Serdar Farhan, Veronika Bruno, et al.
Journal of Hypertension|November 12, 2015
Predictors of response to renal denervation for resistant arterial hypertension: a single center experienceMiklos Rohla, Alexander Nahler, Thomas Lambert, et al.
Wiener Klinische Wochenschrift|September 15, 2016
Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization : A real world experienceMiklos Rohla, Ioannis Tentzeris, Matthias K Freynhofer, et al.
Frontiers in Cardiovascular Medicine|March 29, 2022
Neurotensin and Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary InterventionMaximilian Tscharre, Serdar Farhan, Matthias K Freynhofer, et al.
The American Journal of Cardiology|July 24, 2017
Usefulness of Elevated Levels of Growth Differentiation Factor-15 to Classify Patients With Acute Coronary Syndrome Having Percutaneous Coronary Intervention Who Would Benefit from High-Dose Statin TherapyIoannis Tentzeris, Serdar Farhan, Matthias Karl Freynhofer, et al.
BMJ Open|April 1, 2019
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)Miklos Rohla, Thomas W Weiss, Ladislav Pecen, et al.
Pageof 5